Valneva and Pfizer announce the closing of their equity investment
Pursuant to a share subscription agreement, Pfizer invested €90.5
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring people therapies that dramatically extend and improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of healthcare products, including innovative medicines and vaccines. Every day, Pfizer colleagues work in developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. In line with our responsibility as one of the world’s leading innovative biopharmaceutical companies, we work with healthcare providers, governments and local communities to support and expand access to reliable and affordable healthcare in the whole world. For over 170 years, we’ve worked to make a difference for everyone who counts on us. We regularly post information that may be important to investors on our website at www.pfizer.com. Also, to learn more, visit us at www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
M +33 (0)6 4516 7099
Vice President of Global Investor Relations
M +1 917 815 4520
Valneva forward-looking statements
This press release contains certain forward-looking statements relating to the business of
Pfizer Notice of Disclosure
The information contained in this press release is as of
This release contains forward-looking information about a Lyme disease vaccine candidate, VLA15, as well as a stock subscription agreement and a collaboration and license agreement between Pfizer and
A more detailed description of the risks and uncertainties is available in Pfizer’s Annual Report on Form 10-K for the year ended.
# # #